Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Iberdomide plus dex effective and well tolerated in R/R MM

Niels van de Donk • 7 Dec 2019
ASH 2019
Multiple Myeloma Dexamethasone Iberdomide Lenalidomide Pomalidomide Thalidomide

Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses data from a current phase I/II clinical trial (NCT02773030) of a novel cereblon E3 ligase modulatory compound (CELMoD), iberdomide (CC-220), in relapsed/refractory multiple myeloma (R/R MM). Results show that iberdomide has notable clinical activity and favorable tolerability in heavily pretreated patients with R/R MM. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Niels van de Donk

4:33
Cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
Niels van de Donk • 13 Dec 2021
2:42
Iberdomide plus dexamethasone for heavily pretreated multiple myeloma
Niels van de Donk • 13 Dec 2021
3:03
The future of CAR-T therapy for multiple myeloma
Niels van de Donk • 13 Dec 2021
1:45
Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk • 13 Dec 2021

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals